...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Inorganic Biochemistry: An Interdisciplinary Journal >Recent advances on antimony(III/V) compounds with potential activity against tumor cells
【24h】

Recent advances on antimony(III/V) compounds with potential activity against tumor cells

机译：具有潜在抗肿瘤细胞活性的锑（III / V）化合物的最新进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Antimony one of the heavier pnictogens, has been in medical use against microbes and parasites as well. Antimony-based drugs have been prescribed against leishmaniasis since the parasitic transmission of the tropical disease was understood in the beginning of the 20th century. The activity of arsenic against visceral leishmaniasis led to the synthesis of an array of arsenic-containing parasitic agents, among them the less toxic pentavalent antimonials: Stibosan, Neostibosan, and Ureastibamine. Other antimony drugs followed: sodium stibogluconate (Pentostam) and melglumine antimoniate (Glucantim or Glucantime); both continue to be in use today despite their toxic side effects and increasing loss in potency due to the growing resistance of the parasite against antimony. Antimony compounds and their therapeutic potentials are under consideration from many research groups, while a number of early reviews recording advances of antimony biomedical applications are also available. However, there are only few reports on the screening for antitumor potential of antimony compounds. This review focuses upon results obtained on the anti-proliferative activity of antimony compounds in the past years. This survey shows that antimony(III/V) complexes containing various types of ligands such as thiones, thiosemicarbazones, dithiocarbamates, carboxylic acids, or ketones, nitrogen donor ligands, exhibit selectivity against a variety of cancer cells. The role of the ligand type of the complex is elucidated within this review. The complexes and their biological activity are already reported elsewhere. However quantitative structure-activity relationship (QSAR) modeling studies have been carried out and they are reported for the first time here. (C) 2015 Elsevier Inc. All rights reserved.
机译：锑是一种较重的光合剂，也已在医学上用于抵抗微生物和寄生虫。自从20世纪初人们了解热带疾病的寄生虫传播以来，就已经开出了以锑为基础的药物来对抗利什曼病的处方。砷对内脏利什曼病的活性导致了一系列含砷的寄生虫药物的合成，其中包括毒性较低的五价锑：斯蒂波桑，尼司他波生和Urastibamine。随后还有其他锑药物：stibogluconate钠（Pentostam）和melglumine锑酸（Glucantim或Glucantime）;尽管它们具有毒副作用，并且由于寄生虫对锑的抵抗力不断增强，但两者的效能损失却在不断增加，因此两者至今仍在继续使用。许多研究小组正在考虑锑化合物及其治疗潜力，同时也有许多记录锑生物医学应用进展的早期综述。然而，关于锑化合物的抗肿瘤潜力的筛选的报道很少。这篇综述着眼于过去几年中锑化合物的抗增殖活性。该调查表明，含有各种类型配体（例如硫酮，硫代半氨基甲酮，二硫代氨基甲酸酯，羧酸或酮，氮供体配体）的锑（III / V）络合物对多种癌细胞具有选择性。在本综述中阐明了复合物的配体类型的作用。复合物及其生物学活性已经在其他地方报道过。但是，已经进行了定量构效关系（QSAR）建模研究，并首次在此进行了报道。 （C）2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号